Professor Donal Hollywood
|College address||Department of Radiation Oncology|
|Main department||Radiation Oncology|
|College title||Professor of Clinical Oncology|
|College Telephone||+353 1 896 3234|
|Notes||Consultant Radiation Oncologist at St Luke’s and St James’s Hospital|
|Clinical sub specialties||Breast, Head and Neck, Gastro -oesophageal, Genitourinary and Skin cancers|
|Research Interests||Molecular optimisation of radiation response and the molecular biology of prostate cancer|
Professor Donal Hollywood is the Marie Curie Professor of Clinical Oncology at Trinity College Dublin and the Head of the Academic Unit of Clinical and Molecular Oncology at the College.
He graduated in medicine in 1983 and following initial medical training in Dublin completed formal training in clinical and molecular oncology at the Hammersmith Hospital London & Imperial Cancer Research Fund receiving both the FFRRCSI and FRCR. He completed a clinical research fellowship and PhD program in Molecular Genetics & Oncology at the Imperial Cancer Research Fund in 1992 and was subsequently awarded a Fulbright Scholarship enabling him to work as a research Group Leader in molecular targeting at Baylor College of Medicine prior to returning to Ireland in 1994 as a Consultant Clinical Oncologist and Professor of Clinical Oncology at St. Luke’s and St. James’ Hospitals and Trinity College Dublin.
He has played a major role in strategic cancer service re-organization within Ireland including being Chairperson of the National Expert Group on Radiation Oncology (1999-2003) that resulted in the publication of a pivotal advisory document to the Irish Government on the future structuring of National Cancer Services. He is the acting Chairperson of the National Radiation Oncology Coordinating Group, a Member of the National Radiation Oncology Project Advisory Group and a member of the National Cancer Forum.
He previously served as Director of the National Training Program (Oncology) and is a member of the Examining Board of the RCSI. He is a Visiting Professor at the University of British Columbia, the University of Buenos Aires, and National Cancer Institute. He has held elected positions in Trinity College Dublin, the Faculty of Radiologists (RCSI), the Royal College of Surgeons in Ireland (RCSI), and the Education Board of the Royal College of Radiologists (RCR) in London. He was the founding course director of the European Society for Therapeutic Radiation Oncology (ESTRO) training course in Molecular Oncology.
Prof Hollywood is also a member of the Implementation Group of the NCI-All Ireland Consortium and Chairperson of the Information Technology Subgroup. He has been invited to participate in discussions within the US Presidents Cancer Panel and has won a number of national international awards including a Fulbright Scholarship, ICRF research prize, ESMO / Lilly Research Scholarship, and the St Luke’s Medal.
He has a major interest in molecular oncology and his active research interests include the molecular optimisation of radiation response and the molecular biology of prostate cancer. He has published extensively on his research interests with additional contributions to a number of major textbooks including the Oxford Textbook of Oncology.
In 2008 he became the Clinical Director and Lead Academic for the National Radiation Oncology Program (Ireland), and National Advisor to the National Cancer Control Program (Ireland). Separately in 2008 he was nominated by the ESTRO Board to become the Chair of the ESTRO Clinical Standing Committee.
Peer Reviewed publications
Martin L, Marples B, Coffey M, Lawler M, Hollywood D, Marignol L., Recognition of O6MeG Lesions by MGMT and Mismatch Repair Proficiency may be a Prerequisite for Low-Dose Radiation Hypersensitivity. Radiat Res. 2009 Oct; 172(4):405-13.
McDowell DT, Smith FM, Reynolds JV, Maher SG, Adida C, Crotty P, Gaffney EF, Hollywood D, Mehigan B, Stephens RB, Kennedy MJ., Increased spontaneous apoptosis, but not survivin expression, is associated with histomorphologic response to neoadjuvant chemoradiation in rectal cancer. Int J Colorectal Dis. 2009 Jul 11.
Bacon CL, Daly P, Sheane B, Conneally EC, Browne PV, McCann S, Ni Chongaile M, O'Brian DS, Mc Dermott R, Hollywood D, Wilson L, Vandenberghe E., Successful outcome of patients with relapsed/refractor Hodgkin lymphoma treated with high dose chemotherapy at the National Adult Bone Marrow Transplant Unit at St. James's Hospital. Ir Med J. 2009 Jan; 102(1):26-8.
Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M., The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther. 2009 Jan; 8(2):118-24.
Marignol L, Foley R, Southgate TD, Coffey M, Hollywood D, Lawler M., Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro. J Gene Med. 2009 Feb; 11(2):169-79.
Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG., The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate? J Gene Med. 2008 Sep; 10(9):1032-8.
de Blacam C, Gray J, Boyle T, Kennedy MJ, Hollywood D, Butt J, Griffin M, Nicholson S, Dunne B, Wilson G, McDermott R, Murphy P, Short I, Rowley S, Connolly E, Reynolds JV., Breast cancer outcomes following a national initiative in Ireland to restructure delivery of services for symptomatic disease. Breast. 2008 Aug; 17(4):412-7.
Marignol L, Coffey M, Lawler M, Hollywood D., Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev. 2008 Jun; 34(4):313-27.
Gillham CM, Aherne N, Rowley S, Moore J, Hollywood D, O'Byrne K, Reynolds JV, Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer., Clin Oncol (R Coll Radiol). 2008 Apr; 20(3):227-33.
Gillham CM, Reynolds J, Hollywood D, Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation., World J Surg Oncol. 2007 Aug 23; 5:97.
Marignol L, Coffey M, Hollywood D, Lawler M, Radiation to control transgene expression in tumors., Cancer Biol Ther. 2007 Jul; 6(7):1005-12.
Walshe L, Rowley S, Coffey M, Hollywood D, Kennedy MJ, Gillham C, Ravi N, Reynolds JV, Comparison of two fractionation regimens in the multimodal therapy of cancer of the esophagus., Dis Esophagus. 2007; 20(3):217-24.
Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ, Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer., Ann Surg. 2007 May; 245(5):707-16.
Perry AS, Loftus B, Moroose R, Lynch TH, Hollywood D, Watson RW, Woodson K, Lawler M, In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer., Br J Cancer. 2007 May 21; 96(10):1587-94. Apr 24.
Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, O'Byrne K, Hollywood D, Muldoon C, Reynolds JV, (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response., Br J Cancer. 2006 Nov 6; 95(9):1174-9.
Reynolds JV, Ravi N, Hollywood D, Kennedy MJ, Rowley S, Ryan A, Hughes N, Carey M, Byrne P, Neoadjuvant chemoradiation may increase the risk of respiratory complications and sepsis after transthoracic esophagectomy., J Thorac Cardiovasc Surg. 2006 Sep; 132(3):549-55.
MacGuill M, Mulligan E, Ravi N, Rowley S, Byrne PJ, Hollywood D, Kennedy J, Keeling PN, Reynolds JV, Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer., Dis Esophagus. 2006; 19(4):273-6.
Cunningham MS, White B, Hollywood D, O'Donnell J, Primary thromboprophylaxis for cancer patients with central venous catheters--a reappraisal of the evidence., Br J Cancer. 2006 Jan 30; 94(2):189-94.
Smith FM, Reynolds JV, Kay EW, Crotty P, Murphy JO, Hollywood D, Gaffney EF, Stephens RB, Kennedy MJ, COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy., Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):466-72.
Marignol L, Lawler M, Coffey M, Hollywood D, Achieving hypoxia-inducible gene expression in tumors., Cancer Biol Ther. 2005 Apr; 4(4):359-64.
Foley R, Hollywood D, Lawler M, Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease., Endocr Relat Cancer. 2004 Sep; 11(3):477-88.
Foley R, Lawler M, Hollywood D, Gene-based therapy in prostate cancer., Lancet Oncol. 2004 Aug; 5(8):469-79.